Trial Profile
An expanded access programme of Translarna (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 21 Aug 2014
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 21 Aug 2014 New trial record